BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31375684)

  • 1. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.
    Dammert MA; Brägelmann J; Olsen RR; Böhm S; Monhasery N; Whitney CP; Chalishazar MD; Tumbrink HL; Guthrie MR; Klein S; Ireland AS; Ryan J; Schmitt A; Marx A; Ozretić L; Castiglione R; Lorenz C; Jachimowicz RD; Wolf E; Thomas RK; Poirier JT; Büttner R; Sen T; Byers LA; Reinhardt HC; Letai A; Oliver TG; Sos ML
    Nat Commun; 2019 Aug; 10(1):3485. PubMed ID: 31375684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Family matters: How MYC family oncogenes impact small cell lung cancer.
    Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML
    Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
    Tokgun O; Tokgun PE; Inci K; Akca H
    Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line.
    Supino R; Perego P; Gatti L; Caserini C; Leonetti C; Colantuono M; Zuco V; Carenini N; Zupi G; Zunino F
    Eur J Cancer; 2001 Nov; 37(17):2247-56. PubMed ID: 11677115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer.
    Kim DW; Wu N; Kim YC; Cheng PF; Basom R; Kim D; Dunn CT; Lee AY; Kim K; Lee CS; Singh A; Gazdar AF; Harris CR; Eisenman RN; Park KS; MacPherson D
    Genes Dev; 2016 Jun; 30(11):1289-99. PubMed ID: 27298335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.
    Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC
    Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061
    [No Abstract]   [Full Text] [Related]  

  • 12. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
    Shatat MA; Gauthier B; Yoon S; Yuan E; Yang P; Narla G; Dowlati A; Lee RT
    Cancer Med; 2023 Apr; 12(7):8378-8387. PubMed ID: 36562288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
    Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
    Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
    Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
    Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Bouillez A; Rajabi H; Pitroda S; Jin C; Alam M; Kharbanda A; Tagde A; Wong KK; Kufe D
    Cancer Res; 2016 Mar; 76(6):1538-48. PubMed ID: 26833129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Mak DWS; Li S; Minchom A
    Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
    Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
    Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
    [No Abstract]   [Full Text] [Related]  

  • 20. MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
    Massó-Vallés D; Beaulieu ME; Soucek L
    Expert Opin Ther Targets; 2020 Feb; 24(2):101-114. PubMed ID: 32003251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.